FGF21 — Fibroblast Growth Factor 21
Overview
Pathway Diagram
Mermaid diagram (expand to render)
FGF21 (Fibroblast Growth Factor 21) encodes a member of the FGF19 subfamily of fibroblast growth factors that functions primarily as a metabolic regulator. Originally discovered for its potent effects on glucose metabolism, lipid homeostasis, and insulin sensitivity, FGF21 has emerged as a molecule of significant interest in neuroscience due to its expression in the brain, its ability to cross the blood-brain barrier, and its demonstrated neuroprotective properties["@iwashita2019"][@saxo2015].
FGF21 belongs to the atypical FGF family (along with FGF19 and FGF23) characterized by reduced heparin-binding affinity, which allows them to function as circulating hormones rather than purely paracrine factors. This endocrine nature distinguishes FGF21 from canonical FGFs and has important implications for its therapeutic potential["@yun2013"].
In the nervous system, FGF21 has been shown to protect neurons against various insults, modulate neuroinflammation, influence synaptic plasticity, and support cellular energy metabolism. These functions suggest potential applications in treating neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[@song2018][@khodadadi2019]. Additionally, FGF21's effects on systemic metabolism may provide secondary benefits for brain health through improved vascular function and reduced inflammatory burden.
<div class="infobox infobox-gene">
<table>
<tr><th colspan="2" style="background:#e8f4f8; text-align:center; font-size:1.1em;">Fibroblast Growth Factor 21</th></tr>
<tr><td><strong>Gene Symbol</strong></td><td>FGF21</td></tr>
<tr><td><strong>Full Name</strong></td><td>Fibroblast Growth Factor 21</td></tr>
<tr><td><strong>Chromosome</strong></td><td>12q13</td></tr>
<tr><td><strong>NCBI Gene ID</strong></td><td><a href="https://www.ncbi.nlm.nih.gov/gene/26291" target="_blank">26291</a></td></tr>
<tr><td><strong>OMIM</strong></td><td>609436</td></tr>
<tr><td><strong>Ensembl ID</strong></td><td>ENSG00000163410</td></tr>
<tr><td><strong>UniProt ID</strong></td><td><a href="https://www.uniprot.org/uniprot/Q9NS73" target="_blank">Q9NS73</a></td></tr>
<tr><td><strong>Protein Length</strong></td><td>209 amino acids</td></tr>
<tr><td><strong>Molecular Weight</strong></td><td>22.5 kDa</td></tr>
<tr><td><strong>Associated Diseases</strong></td><td>[Alzheimer's Disease](/diseases/alzheimers-disease), [Parkinson's Disease](/diseases/parkinsons-disease), Metabolic Syndrome, Type 2 Diabetes</td></tr>
</table>
</div>
Protein Structure and Function
FGF19 Subfamily Organization
The FGF19 subfamily consists of three members in humans:
- FGF19: Enteroendocrine hormone regulating bile acid metabolism
- FGF21: Metabolic regulator of glucose, lipid, and energy homeostasis
- FGF23: Phosphate and vitamin D regulator (discussed in separate page)
These proteins share the property of having reduced heparin-binding affinity, which allows them to enter the circulation and act as endocrine factors. This is in contrast to canonical FGFs that remain localized at sites of production due to high heparin-binding affinity.
Structural Features
FGF21 has several distinctive structural features[@inagaki2007]:
- N-terminal signal peptide: Directs secretion
- FGF core domain: Receptor binding (conserved β-trefoil fold)
- Heparin-binding domain: Reduced affinity compared to canonical FGFs
- C-terminal tail: Contributes to receptor specificity
The three-dimensional structure of FGF21 reveals the characteristic FGF fold but with surface properties that determine its specific receptor interactions and co-factor requirements.
Receptor Interactions
FGF21 signals through specific FGF receptor (FGFR) combinations[@tanaka2016]:
- Primary receptors: FGFR1c, FGFR2c, FGFR3c
- Co-factor requirement: β-Klotho (essential for signaling)
- Tissue distribution: Limited by β-Klotho expression
The requirement for β-Klotho as a co-receptor restricts FGF21 signaling to tissues expressing this protein, including liver, adipose tissue, pancreas, and specific brain regions.
Expression in the Nervous System
Brain Expression Patterns
FGF21 is expressed in various regions of the brain[@tomita2013]:
- Hypothalamus: High expression in arcuate nucleus and paraventricular nucleus
- Hippocampus: CA1-CA3 regions and dentate gyrus
- Cerebral cortex: Layer-specific expression
- Cerebellum: Purkinje cells and granular layer
- Brainstem: Specific nuclei
This widespread expression suggests diverse functions in brain physiology and pathology.
Cellular Expression
FGF21 is expressed in multiple neural cell types:
- Neurons: Both excitatory and inhibitory neurons
- Astrocytes: GFAP-positive astrocytes
- Microglia: Resident immune cells
- Oligodendrocytes: Myelin-producing cells
Cell type-specific expression patterns may underlie the diverse effects of FGF21 on neural function.
Regulation of Expression
FGF21 expression in the brain is regulated by:
- Metabolic status: Fasting and ketosis increase expression
- Nutritional signals: Ketone bodies, free fatty acids
- Stress: Glucocorticoid signaling affects expression
- Aging: Expression changes with age
This regulation suggests that FGF21 may serve as a metabolic integrator linking peripheral metabolic status to brain function.
Blood-Brain Barrier Transport
Transport Mechanism
FGF21 can cross the blood-brain barrier through a saturable transport system[@hsuchou2012]:
- Transport type: Carrier-mediated transcytosis
- Brain regions: Areas with less restrictive BBB
- Functional significance: Peripheral FGF21 can affect brain function
This transport property has important implications for therapeutic delivery, as peripheral administration of FGF21 can directly affect the brain.
Implications for Therapy
The ability of FGF21 to cross the BBB offers advantages for neurological applications:
- Peripheral delivery: Systemic administration reaches the brain
- Sustained effects: Long half-life allows continuous signaling
- Non-invasive: Avoids direct brain delivery
These properties have motivated interest in developing FGF21-based therapies for neurological disorders.
FGF21 is primarily known for its metabolic effects[@yun2013][@bookout2013]:
- Glucose homeostasis: Improves insulin sensitivity
- Lipid metabolism: Lowers triglycerides and cholesterol
- Energy expenditure: Increases calorie expenditure
- Body weight: Reduces body weight in obesity
These peripheral effects may indirectly benefit brain health through improved vascular function, reduced inflammation, and enhanced metabolic support.
FGF21 affects brain metabolism in several ways:
- Glucose utilization: Modulates neuronal glucose uptake
- Mitochondrial function: Enhances mitochondrial efficiency[@chen2019]
- Lipid metabolism: Affects brain lipid composition
- Ketone utilization: May enhance ketone body use
These metabolic effects position FGF21 as a potential therapeutic for neurodegenerative diseases characterized by metabolic dysfunction.
Neuroprotection
Neuronal Survival
FGF21 provides neuroprotection through multiple mechanisms[@iwashita2019][@song2018]:
- Anti-apoptotic effects: Blocks intrinsic apoptosis pathway
- Anti-oxidative: Reduces reactive oxygen species
- Anti-inflammatory: Modulates glial activation
- Metabolic support: Enhances cellular energetics
These protective effects have been demonstrated in various models of neurodegeneration.
Alzheimer's Disease Models
FGF21 has shown promise in AD models[@khodadadi2019]:
- Amyloid pathology: Reduces amyloid-beta accumulation
- Tau pathology: Attenuates tau phosphorylation
- Cognitive function: Improves memory performance
- Synaptic function: Preserves synaptic markers
The multi-target nature of FGF21 makes it attractive for AD, which involves multiple pathological processes.
Parkinson's Disease Models
In PD models[@song2018]:
- Dopaminergic neurons: Protects substantia nigra neurons
- Motor behavior: Improves behavioral outcomes
- Alpha-synuclein: May affect aggregation
- Neuroinflammation: Reduces microglial activation
FGF21's ability to protect dopaminergic neurons is particularly relevant for PD.
Mechanism of Neuroprotection
The neuroprotective mechanisms of FGF21 include:
- FGFR/β-Klotho signaling: Activates downstream pathways
- ERK activation: Promotes cell survival
- AKT activation: Enhances survival signaling
- AMPK activation: Increases metabolic efficiency
These pathways converge on pro-survival and anti-apoptotic outcomes.
Neuroinflammation
Anti-inflammatory Effects
FGF21 modulates neuroinflammation through several mechanisms[@yang2017]:
- Microglial activation: Shift from M1 to M2 phenotype
- Cytokine production: Reduces pro-inflammatory cytokines
- NF-κB pathway: Inhibits this key inflammatory pathway
- Glial scar: Modulates scar formation
The anti-inflammatory properties of FGF21 are relevant for neurodegenerative diseases where neuroinflammation contributes to pathology.
Inflammatory Diseases
FGF21 may be beneficial for:
- Alzheimer's disease: Reduces microglial activation
- Parkinson's disease: Modifies neuroinflammation
- Multiple sclerosis: Potential immunomodulatory effects
- Stroke: Reduces post-ischemic inflammation
These applications are under active investigation.
Synaptic Plasticity and Cognition
Effects on Synapses
FGF21 influences synaptic plasticity[@lee2018]:
- Synaptic formation: Promotes new synapse formation
- Synaptic function: Enhances synaptic transmission
- LTP induction: Facilitates long-term potentiation
- Memory consolidation: Supports memory formation
These effects suggest roles in learning and memory.
Cognitive Function
FGF21 affects cognitive function[@mironova2016]:
- Spatial memory: Improves hippocampal-dependent memory
- Object recognition: Enhances novel object recognition
- Working memory: Supports executive function
- Aging: May counteract age-related cognitive decline
The cognitive effects of FGF21 are mediated through its actions on synaptic plasticity and neurogenesis.
Autophagy and Cellular Quality Control
Autophagy Regulation
FGF21 modulates autophagy in neural cells[@liu2017]:
- mTOR inhibition: Reduces mTOR activity
- Autophagosome formation: Promotes autophagy initiation
- Lysosomal function: Enhances clearance
- Protein aggregation: May reduce aggregation
Enhanced autophagy may contribute to neuroprotection by clearing damaged proteins and organelles.
Implications for Neurodegeneration
Autophagy modulation by FGF21 may benefit:
- Protein aggregate clearance: Removes misfolded proteins
- Mitochondrial quality: Clears damaged mitochondria
- Cellular stress: Reduces ER stress
- Neuronal survival: Maintains cellular homeostasis
These quality control mechanisms are particularly important in diseases characterized by protein aggregation.
Oxidative Stress
Antioxidant Effects
FGF21 has antioxidant properties[@fang2019]:
- ROS reduction: Decreases reactive oxygen species
- Nrf2 activation: Activates antioxidant response
- Mitochondrial protection: Preserves mitochondrial function
- Enzyme induction: Increases antioxidant enzymes
Oxidative stress is a key contributor to neurodegeneration, making antioxidant effects valuable.
Neuroprotection
The antioxidant effects of FGF21 contribute to:
- Neuronal survival: Protects against oxidative damage
- DNA integrity: Maintains genomic stability
- Lipid peroxidation: Reduces membrane damage
- Protein oxidation: Prevents protein carbonylation
These protective effects may slow neurodegenerative processes.
Insulin Signaling
Brain Insulin Signaling
FGF21 affects insulin signaling in the brain[@lu2018]:
- Insulin receptor: Modulates receptor sensitivity
- IRS-1 signaling: Affects downstream signaling
- PI3K/AKT pathway: Enhances insulin effects
- Glucose transport: May affect GLUT expression
Insulin resistance in the brain is increasingly recognized as a contributor to neurodegeneration.
FGF21 may bridge metabolic disease and neurodegeneration:
- Type 2 diabetes: Increases AD risk
- Obesity: Associated with cognitive decline
- Insulin resistance: Affects brain function
- Therapeutic potential: Addresses common mechanisms
This connection highlights the importance of metabolic health for brain function.
Genetic Variants and Disease Risk
Neurological Disease Associations
Studies have explored FGF21 variants in neurological disease[@ren2019]:
- Alzheimer's disease: Some associations reported
- Parkinson's disease: Limited evidence
- Stroke: Possible associations
- Cognitive function: Variant effects on cognition
These genetic studies provide additional evidence for FGF21's role in brain health.
FGF21 variants are more strongly associated with:
- Type 2 diabetes: Clear genetic associations
- Obesity: Variant effects on body weight
- Dyslipidemia: Triglyceride associations
- Metabolic syndrome: Combined metabolic effects
The metabolic effects of FGF21 variants are better characterized than neurological effects.
Therapeutic Implications
Drug Development
FGF21-based therapeutics are under development[@kharitonenkov2015]:
- Recombinant proteins: FGF21 analogs
- FGF21 mimetics: Engineered receptor agonists
- Small molecules: β-Klotho agonists
- Gene therapy: Viral vector delivery
These approaches aim to exploit the beneficial effects of FGF21.
Clinical Applications
Potential neurological applications include:
- Alzheimer's disease: Disease modification
- Parkinson's disease: Neuroprotection
- Metabolic encephalopathy: Cognitive protection
- Aging: Cognitive enhancement
The broad neuroprotective profile of FGF21 supports multiple potential applications.
Challenges
Significant challenges remain:
- BBB penetration: While crossing occurs, optimization needed
- Dosing: Determining optimal therapeutic window
- Side effects: Understanding long-term safety
- Combination therapy: Synergy with other approaches
These challenges are being addressed through ongoing research.
Biomarker Potential
Diagnostic Applications
FGF21 has biomarker potential[@admasu2018]:
- Peripheral levels: Detectable in blood
- Disease associations: Altered in neurodegeneration
- Progression markers: May track disease progression
- Treatment response: May indicate therapeutic effects
Peripheral FGF21 measurement offers a non-invasive approach.
Limitations
Challenges for biomarker use include:
- Specificity: Not disease-specific
- Metabolic confounders: Affected by metabolic status
- Overlap: Significant overlap between groups
- Standardization: Lack of standardized assays
Further validation is needed for clinical implementation.
Signaling Pathways
FGF21 Signaling Cascade
FGF21 → FGFR/β-Klotho complex → Receptor autophosphorylation
↓
Adapter protein recruitment
↓
RAS/MAPK, PI3K/AKT, PLCγ pathways
↓
Cellular response: metabolic regulation, survival, plasticity
Cross-talk with Neurodegeneration Pathways
FGF21 interfaces with neurodegeneration through:
- Amyloid processing: Effects on APP metabolism
- Tau phosphorylation: May influence kinase/phosphatase balance
- Neuroinflammation: Regulates glial responses
- Autophagy: Modulates protein clearance
Research Models
Animal Models
Key models for studying FGF21:
- Transgenic mice: FGF21 overexpression
- Knockout mice: FGF21 deficiency
- Dietary models: Metabolic disease models
- Neurodegeneration models: AD and PD models
Cellular Models
Research approaches include:
- Primary neurons: Cultured neural cells
- iPSC-derived neurons: Patient-specific models
- Organoid systems: Brain organoid models
- Cell lines: Neural cell lines
Cross-links
- [Fibroblast Growth Factors](/proteins/fibroblast-growth-factors)
- [FGF Signaling](/mechanisms/fgfr-signaling)
- [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
- [Metabolism and Neurodegeneration](/mechanisms/metabolism-neurodegeneration)
- [Neuroinflammation](/mechanisms/neuroinflammation)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
See Also
- [Genes Index](/genes)
- [Growth Factors](/proteins/growth-factors)
- [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
References
admasu2018, FGF21 as a biomarker in neurodegenerative disease (2018)
bookout2013, FGF21 and energy homeostasis regulation (2013)
chen2019, FGF21 and mitochondrial function in neurons (2019)
fang2019, FGF21 and oxidative stress in neural cells (2019)
hsuchou2012, FGF21 transport across the blood-brain barrier (2012)
inagaki2007, FGF21 functions as a metabolic regulator (2007)
iwashita2019, FGF21 in neuroprotection and neural stem cells (2019)
kharitonenkov2015, FGF21 pharmacology and therapeutic potential (2015)
khodadadi2019, FGF21 in Alzheimer's disease models (2019)
lee2018, FGF21 in synaptic plasticity and memory (2018)
liu2017, FGF21 and autophagy in neurodegeneration (2017)
lu2018, FGF21 and insulin signaling in the brain (2018)
mironova2016, FGF21 and cognitive function in aging (2016)
ren2019, FGF21 variants and neurological disease susceptibility (2019)
saxo2015, FGF21 and metabolic stress in the brain (2015)
song2018, FGF21 protects against dopaminergic neurodegeneration (2018)
tanaka2016, FGF21 receptor expression in the brain (2016)
tomita2013, FGF21 expression in the brain and neurological function (2013)
yang2017, FGF21 and neuroinflammation modulation (2017)
yun2013, FGF21 as a therapeutic target for metabolic disease (2013)
Pathway Diagram
The following diagram shows the key molecular relationships involving FGF21 — Fibroblast Growth Factor 21 discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)